1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol | 216311-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol
• 英文别名: 1-BENZYL-4-HYDROXY-4-(4-FLUORO-2-METHYLPHENYL)PIPERIDINE；1-benzyl-4-(4-fluoro-2-methyl)-phenyl-4-piperidinol
• CAS: 216311-09-0
• 化学式: C₁₉H₂₂FNO
• 分子量: 299.388
• InChiKey: SCVKNEWYONBXOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol 在 氢气 、 palladium(II) hydroxide 、 对甲苯磺酸 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 甲苯 为溶剂， 20.0~60.0 ℃ 、101.33 kPa 条件下， 反应 106.0h， 生成 1-{3-[4-(4-fluoro-2-methylphenyl)piperidin-1-yl]propanoyl}-N,N-dimethylindoline-(2S)-2-carboxamide monocitrate
  参考文献：
  名称：

  1-（β-氨基取代-β-丙氨酰）-N，N-二甲基二氢吲哚-2-羧酰胺类化合物作为痛敏肽/孤儿蛋白FQ受体的新型非肽拮抗剂的发现：有效的设计，合成和结构-活性关系研究

  摘要：

  自从发现内源性伤害感受器/孤儿蛋白FQ（N / OFQ）肽和N / OFQ肽（NOP）受体[或阿片受体样1（ORL1）受体]以来，已经报道了其结构，分布和药理学细节。N / OFQ和NOP受体位于参与情绪活动整合的皮层区，并位于脊髓，周围神经系统或其他与疼痛以及尿液信号传递相关的周围组织中，其模式不同于啮齿动物或灵长类动物中的经典阿片肽及其受体。此外，N / OFQ-NOP受体系统在各种人类生理机能的调节中起着重要作用，例如抑郁症效应，食欲亢进效应和血压效应。在这项研究中，N，N-二甲基二氢吲哚-2-羧酰胺在体外进行了研究，以阐明鉴定和开发有效和选择性NOP受体拮抗剂的结构要求，从而发现了1- {3- [4-（取代苯基）哌啶-1-基]酰基]丙酰基} -N，N-二甲基二氢吲哚-2-羧酰胺类似物，其显示有效的和选择性的人NOP（hNOP）受体结合亲和力和有效的hNOP受体拮抗剂活性。有效和选择

  DOI：

  10.1016/j.ejmech.2012.07.021
• 作为产物：
  描述：

  2-溴-5-氟甲苯 在 碘 、 magnesium 、 magnesium bromide 作用下， 以 四氢呋喃 为溶剂， 反应 7.25h， 生成 1-benzyl-4-(4-fluoro-2-methylphenyl)piperidin-4-ol
  参考文献：
  名称：

  1-（β-氨基取代-β-丙氨酰）-N，N-二甲基二氢吲哚-2-羧酰胺类化合物作为痛敏肽/孤儿蛋白FQ受体的新型非肽拮抗剂的发现：有效的设计，合成和结构-活性关系研究

  摘要：

  自从发现内源性伤害感受器/孤儿蛋白FQ（N / OFQ）肽和N / OFQ肽（NOP）受体[或阿片受体样1（ORL1）受体]以来，已经报道了其结构，分布和药理学细节。N / OFQ和NOP受体位于参与情绪活动整合的皮层区，并位于脊髓，周围神经系统或其他与疼痛以及尿液信号传递相关的周围组织中，其模式不同于啮齿动物或灵长类动物中的经典阿片肽及其受体。此外，N / OFQ-NOP受体系统在各种人类生理机能的调节中起着重要作用，例如抑郁症效应，食欲亢进效应和血压效应。在这项研究中，N，N-二甲基二氢吲哚-2-羧酰胺在体外进行了研究，以阐明鉴定和开发有效和选择性NOP受体拮抗剂的结构要求，从而发现了1- {3- [4-（取代苯基）哌啶-1-基]酰基]丙酰基} -N，N-二甲基二氢吲哚-2-羧酰胺类似物，其显示有效的和选择性的人NOP（hNOP）受体结合亲和力和有效的hNOP受体拮抗剂活性。有效和选择

  DOI：

  10.1016/j.ejmech.2012.07.021

文献信息

• 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US06245773B1

  公开（公告）日：2001-06-12

  This invention is directed to dihydropyrimidine compounds of the following formula: which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  该发明涉及以下结构的二氢嘧啶化合物，这些化合物是人类α1A受体的选择性拮抗剂。该发明还涉及利用这些化合物降低眼压、抑制胆固醇合成、放松下尿路组织、治疗良性前列腺增生、阳痿、心律失常以及治疗任何需要对α1A受体进行拮抗的疾病。该发明进一步提供了一种包含上述定义化合物的治疗有效量和药用可接受载体的药物组合物。
• DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
  申请人：——

  公开号：US20030082623A1

  公开（公告）日：2003-05-01

  This invention provides an isolated nucleic acid encoding a human MCH1 receptor, a purified human MCH1 receptor, vectors comprising isolated nucleic acid encoding a human MCH1 receptor, cells comprising such vectors, antibodies directed to a human MCH1 receptor, nucleic acid probes useful for detecting nucleic acid encoding human MCH1 receptors, antisense oligonucleotides complementary to unique sequences of nucleic acid encoding human MCH1 receptors, transgenic, nonhuman animals which express DNA encoding a normal or mutant human MCH1 receptor, methods of isolating a human MCH1 receptor, methods of treating an abnormality that is linked to the activity of a human MCH1 receptor, as well as methods of determining binding of compounds to mammalian MCH1 receptors. This invention provides a method of modifying the feeding behavior of a subject which comprises administering to the subject an amount of an MCH1 antagonist effective to decrease the body mass of the subject and/or decrease the consumption of food by the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of an MCH1 antagonist effective to treat the subject's depression and/or anxiety.

  这项发明提供了编码人类MCH1受体的孤立核酸，纯化的人类MCH1受体，包括编码人类MCH1受体的孤立核酸的载体，包含这种载体的细胞，针对人类MCH1受体的抗体，用于检测编码人类MCH1受体的核酸探针，互补于编码人类MCH1受体独特序列的反义寡核苷酸，表达编码正常或突变人类MCH1受体的转基因非人类动物，孤立人类MCH1受体的分离方法，治疗与人类MCH1受体活性相关的异常的方法，以及确定化合物与哺乳动物MCH1受体结合的方法。这项发明提供了一种修改受试者摄食行为的方法，包括向受试者投与足以减少受试者体重和/或减少受试者食物摄入量的MCH1拮抗剂的量。这项发明还提供了一种治疗患有抑郁和/或焦虑的受试者的方法，包括向受试者投与足以治疗受试者抑郁和/或焦虑的MCH1拮抗剂的量。
• Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
  申请人：——

  公开号：US20030069261A1

  公开（公告）日：2003-04-10

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

  这项发明涉及选择性拮抗黑素浓集激素-1（MCH1）受体的化合物。该发明提供了一种包括所述化合物的治疗有效量和药学可接受载体的药物组合物。该发明提供了一种通过结合本发明化合物的治疗有效量和药学可接受载体制备的药物组合物。该发明还提供了一种制备药物组合物的方法，包括结合本发明化合物的治疗有效量和药学可接受载体。该发明还提供了一种修改受试者进食行为的方法，包括向受试者投与本发明化合物的有效量以减少受试者的食物摄入量。该发明还提供了一种治疗受试者进食障碍的方法，包括向受试者投与本发明化合物的有效量以减少受试者的食物摄入量。在该发明实施方式中，进食障碍可以是暴食症、暴食症神经质或肥胖症。
• [EN] SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF<br/>[FR] ANTAGONISTES SELECTIFS DES RECEPTEURS (MCH1) D'HORMONE-1 DE CONCENTRATION DE LA MELANINE ET UTILISATION DE CEUX-CI
  申请人：SYNAPTIC PHARMARCEUTICAL CORP

  公开号：WO2002006245A1

  公开（公告）日：2002-01-24

  This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of modifying feeding behavior of a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. This invention further provides a method of treating a feeding disorder in a subject which comprises administering to the subject an amount of a compound of the invention effective to decrease the consumption of food by the subject. In an embodiment of the invention, the feeding disorder is bulimia, bulimia nervosa or obesity.

  本发明涉及选择性拮抗黑色素浓集激素-1（MCH1）受体的化合物。本发明提供一种制药组合物，包括本发明的化合物的治疗有效量和药学上可接受的载体。本发明提供了一种制药组合物，其由本发明的化合物的治疗有效量和药学上可接受的载体组合而成。本发明还提供一种制备制药组合物的方法，包括将本发明的化合物的治疗有效量和药学上可接受的载体组合。本发明还提供了一种修改受试者进食行为的方法，包括向受试者施用本发明的化合物的有效量，以减少受试者的食物摄入量。本发明还提供了一种治疗受试者进食障碍的方法，包括向受试者施用本发明的化合物的有效量，以减少受试者的食物摄入量。在本发明的实施方式中，进食障碍是贪食症、神经性贪食症或肥胖症。
• Dihydropyrimidines and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20020010186A1

  公开（公告）日：2002-01-24

  This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr; 1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr; 1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

  这项发明涉及二氢嘧啶化合物，它们是人类α1A受体的选择性拮抗剂。此发明还涉及使用这些化合物降低眼压、抑制胆固醇合成、放松下尿路组织、治疗良性前列腺增生、阳痿、心律失常和治疗任何需要拮抗α1A受体的疾病。该发明还提供一种制药组合物，包括上述定义化合物的治疗有效量和药学可接受的载体。